Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lab21 gains Ark heart attack diagnostics licence:

This article was originally published in Clinica

Executive Summary

Hampshire, UK-based diagnostics group Lab21 has gained exclusive UK and international rights to market Ark Therapeutics' oxidised low-density lipoprotein (Ox-LDL) auto-antibody diagnostic test kit. The Ox-LDL test is a CE-marked heart attack risk assessment system and will be further trialled by Lab21 until it is ready for launch. Thereafter, Lab21 will conduct all sales and marketing activities for the product. Ark (London, UK) will receive a mix of up-front and milestone payments, together with a 5% royalty on future sales of the test. Both companies are targeting the cardiovascular disease market - according to Ark, one in five males and one in six females in the UK die of cardiovascular disease.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT050021

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel